Skip to content

What Now, What Next? Appropriate management for mUC
Tweetorial #2: Second- and Subsequent-line Therapy
*Pre-assessment*

Before you view this activity, please take this pre-assessment. Taking this pre-assessment does not immediately qualify learners to earn credit. 

Certificates of credit will only be sent to learners who also receive a passing score on the post-test (separate from this survey), and fill out the evaluation form and application for credit.
1.What are your credentials?(Required.)
2.What is your community of practice?
3.68yo female with metastatic urothelial carcinoma (mUC)
  • Status post treatment with enfortumab vedotin and pembrolizumab
  • On pembrolizumab monotherapy for 12 months
  • FGFR3 and cisplatin eligible
  • Presents with new liver metastases
In your practice, what would you use next?(Required.)
4.74yo female status post treatment with gem/ + cisplatin
  • Avelumab maintenance x12m
  • 🧬No FGFR3 alterations, HER2 IHC 0
  • Presents with new liver mets
What treatment should you use next? (Required.)
5.67 year old male patient with mUC status post treatment with EV+P
  • FGFR3 alteration
  • Treated with erdafitinib in the second-line
  • Serum phosphate 8.0 mg/dL
What should you do next? (Required.)
6.Please let us know who you are so we can connect your responses to your post-test & application to claim CME credit (completed after participating in the activity).

Completing the fields below does not immediately qualify you for a CME certificate. Only after completing the post-survey & evaluation form will a certificate be issued.

*Please note that we will not forward or sell your contact information.
🔗 Proceed to activity on www.x.com (only available after program launch date)
🔗 Proceed to activity post-survey
(post-survey completion must occur on or after activity launch date and prior to activity expiration date to be valid for claiming credit)
Privacy & Cookie Notice